Preface to the third edition,. Preface to the first edition,. Acknowledgements,. 1 Introduction, . 1.1 The nature of fungi,. 1.2 Classification and nomenclature of fungi and fungal diseases,.

1.3 Fungi as human pathogens,. 1.3.1 The superficial mycoses,. 1.3.2 The subcutaneous mycoses,.

1.3.3 The systemic mycoses,. 1.4 The changing pattern of fungal infection,. 1.5 New directions in diagnosis,. 1.

6 New directions in treatment and prevention,. 2 Laboratory diagnosis of fungal infection,. 2.1 Introduction, . 2.2 Collection of specimens,. 2.2.

1 Skin, nails and hair,. 2.2.2 Mucous membranes,. 2.2.3 Ear,. 2.

2.4 Eye,. 2.2.5 Blood,. 2.2.6 Cerebrospinal fluid,.

2.2.7 Urine,. 2.2.8 Other fluids,. 2.2.

9 Lower respiratory tract specimens,. 2.2.10 Pus,. 2.2.11 Bone marrow,. 2.

2.12 Tissue,. 2.3 Specimens for serological tests,. 2.4 Specimens for antifungal drug level determinations,. 2.5 Transport of specimens,.

2.6 Interpretation of laboratory test results,. 2.6.1 Direct microscopic examination,. 2.6.2 Histopathological examination,.

2.6.3 Culture,. 2.6.4 Serological tests,. 2.7 Molecular diagnosis of fungal infection,.

3 Antifungal drugs, . 3.1 Introduction,. 3.2 Amphotericin B,. 3.2.1 Mechanism of action,.

3.2.2 Spectrum of action,. 3.2.3 Acquired resistance,. 3.2.

4 Pharmacokinetics,. 3.2.5 Pharmaceutics,. 3.2.6 Therapeutic use,. 3.

2.7 Mode of administration,. 3.2.8 Adverse reactions,. 3.2.9 Drug interactions,.

3.3 Other polyene compounds for topical administration,. 3.3.1 Natamycin,. 3.3.2 Nystatin,.

3.4 Fluconazole,. 3.4.1 Mechanism of action,. 3.4.2 Spectrum of action,.

3.4.3 Acquired resistance,. 3.4.4 Pharmacokinetics,. 3.4.

5 Pharmaceutics,. 3.4.6 Therapeutic use,. 3.4.7 Mode of administration,. 3.

4.8 Adverse reactions,. 3.4.9 Drug interactions,. 3.5 Itraconazole,. 3.

5.1 Mechanism of action,. 3.5.2 Spectrum of action,. 3.5.3 Acquired resistance,.

3.5.4 Pharmacokinetics,. 3.5.5 Pharmaceutics,. 3.5.

6 Therapeutic use,. 3.5.7 Mode of administration,. 3.5.8 Adverse reactions,. 3.

5.9 Drug interactions,. 3.6 Ketoconazole,. 3.6.1 Mechanism of action,. 3.

6.2 Spectrum of action,. 3.6.3 Acquired resistance,. 3.6.4 Pharmacokinetics,.

3.6.5 Pharmaceutics,. 3.6.6 Therapeutic use,. 3.6.

7 Mode of administration,. 3.6.8 Adverse reactions,. 3.6.9 Drug interactions,. 3.

7 Voriconazole,. 3.7.1 Mechanism of action,. 3.7.2 Spectrum of action,. 3.

7.3 Acquired resistance,. 3.7.4 Pharmacokinetics,. 3.7.5 Pharmaceutics,.

3.7.6 Therapeutic use,. 3.7.7 Mode of administration,. 3.7.

8 Adverse reactions,. 3.7.9 Drug interactions,. 3.8 Other imidazole compounds for topical administration,. 3.8.

1 Bifonazole,. 3.8.2 Butoconazole,. 3.8.3 Clotrimazole,. 3.

8.4 Econazole nitrate,. 3.8.5 Fenticonazole nitrate,. 3.8.6 Isoconazole nitrate,.

3.8.7 Miconazole nitrate,. 3.8.8 Oxiconazole,. 3.8.

9 Sulconazole nitrate,. 3.8.10 Terconazole,. 3.8.11 Tioconazole,. 3.

9 Terbinafine,. 3.9.1 Mechanism of action,. 3.9.2 Spectrum of action,. 3.

9.3 Acquired resistance,. 3.9.4 Pharmacokinetics,. 3.9.5 Pharmaceutics,.

3.9.6 Therapeutic use,. 3.9.7 Mode of administration,. 3.9.

8 Adverse reactions,. 3.9.9 Drug interactions,. 3.10 Other allylamine compounds for topical administration,. 3.10.

1 Naftifine. 3.11 Caspofungin,. 3.11.1 Mechanism of action,. 3.11.

2 Spectrum of action,. 3.11.3 Acquired resistance,. 3.11.4 Pharmacokinetics,. 3.

11.5 Pharmaceutics,. 3.11.6 Therapeutic use,. 3.11.7 Mode of administration,.

3.11.8 Adverse reactions,. 3.11.9 Drug interactions,. 3.12 Flucytosine,.

3.12.1 Mechanism of action,. 3.12.2 Spectrum of action,. 3.12.

3 Acquired resistance,. 3.12.4 Pharmacokinetics,. 3.12.5 Pharmaceutics,. 3.

12.6 Therapeutic use,. 3.12.7 Mode of administration,. 3.12.8 Adverse reactions,.

3.12.9 Drug interactions,. 3.13 Griseofulvin,. 3.13.1 Mechanism of action,.

3.13.2 Spectrum of action,. 3.13.3 Acquired resistance,. 3.13.

4 Pharmacokinetics,. 3.13.5 Pharmaceutics,. 3.13.6 Therapeutic use,. 3.

13.7 Mode of administration,. 3.13.8 Adverse reactions,. 3.13.9 Drug interactions,.

3.14 Other miscellaneous compounds for topical administration,. 3.14.1 Amorolfine hydrochloride,. 3.14.2 Butenafine hydrochloride,.

3.14.3 Ciclopirox,. 3.14.4 Haloprogin,. 3.14.

5 Tolnaftate,. 3.15 Empirical treatment of suspected fungal infection in the neutropenic patient,. 3.16 Prophylactic treatment for prevention of fungal infection,. 3.17 Laboratory monitoring,. 3.

17.1 Antifungal drug susceptibility testing,. 3.17.2 Monitoring of blood concentrations of antifungal drugs,. 4 Dermatophytosis, . 4.1 Introduction,.

4.2 The causal organisms and their habitat,. 4.3 Laboratory diagnosis of dermatophytosis,. 4.4 Tinea capitis,. 4.4.

1 Definition,. 4.4.2 Geographical distribution,. 4.4.3 Epidemiology,. 4.

4.4 Clinical manifestations,. 4.4.5 Differential diagnosis,. 4.4.6 Essential investigations and their interpretation,.

4.4.7 Management,. 4.4.8 Prevention,. 4.5 Tinea corporis,.

4.5.1 Definition,. 4.5.2 Geographical distribution,. 4.5.

3 Epidemiology,. 4.5.4 Clinical manifestations,. 4.5.5 Differential diagnosis,. 4.

5.6 Essential investigations and their interpretation,. 4.5.7 Management,. 4.5.8 Prevention,.

4.6 Tinea cruris,. 4.6.1 Definition,. 4.6.2 Geographical distribution,.

4.6.3 Epidemiology,. 4.6.4 Clinical manifestations,. 4.6.

5 Differential diagnosis,. 4.6.6 Essential investigations and their interpretation,. 4.6.7 Management,. 4.

6.8 Prevention,. 4.7 Tinea pedis. 4.74.7.1 Definition,.

4.7.2 Geographical distribution,. 4.7.3 Epidemiology,. 4.7.

4 Clinical manifestations,. 4.7.5 Differential diagnosis,. 4.7.6 Essential investigations and their interpretation,. 4.

7.7 Management,. 4.7.8 Prevention,. 4.8 Tinea manuum,. 4.

8.1 Definition,. 4.8.2 Geographical distribution,. 4.8.3 Epidemiology,.

4.8.4 Clinical manifestations,. 4.8.5 Differential diagnosis,. 4.8.

6 Essential investigations and their interpretation,. 4.8.7 Management,. 4.8.8 Prevention,. 4.

9 Tinea unguium,. 4.9.1 Definition,. 4.9.2 Geographical distribution,. 4.

9.3 Epidemiology,. 4.9.4 Clinical manifestations,. 4.9.5 Differential diagnosis,.

4.9.6 Essential investigations and their interpretation,. 4.9.7 Management,. 4.9.

8 Prevention,. 5 Superficial candidosis, . 5.1 Definition,. 5.2 Geographical distribution,. 5.3 The causal organisms and their habitat,.

5.4 Epidemiology,. 5.5 Clinical manifestations,. 5.55.5.1 Oropharyngeal candidosis,.

5.55.5.2 Vaginal candidosis,. 5.55.5.3 Penile candidosis,.

5.55.5.4 Cutaneous candidosis,. 5.5.5 Candida nail infection,. 5.

5.6 Chronic mucocutaneous candidosis,. 5.6 Essential investigations and their interpretation,. 5.7 Management,. 5.7.

1 Oropharyngeal candidosis,. 5.7.2 Vaginal candidosis,. 5.7.3 Penile candidosis,. 5.

7.4 Cutaneous candidosis,. 5.7.5 Candida nail infection,. 5.7.6 Chronic mucocutaneous candidosis,.

5.8 Prevention,. 6 Other cutaneous fungal infections, . 6.1 Pityriasis versicolor,. 6.1.1 Definition,.

6.1.2 Geographical distribution,. 6.1.3 The causal organisms and their habitat,. 6.1.

4 Epidemiology,. 6.1.5 Clinical manifestations,. 6.1.6 Differential diagnosis,. 6.

1.7 Essential investigations and their interpretation,. 6.1.8 Management,. 6.2 Other Malassezia infections,. 6.

2.1 Malassezia folliculitis,. 6.2.2 Seborrhoeic dermatitis,. 6.3 Piedra,. 6.

4 White piedra,. 6.4.1 Definition,. 6.4.2 Geographical distribution,. 6.

4.3 The causal organisms and their habitat,. 6.4.4 Epidemiology. 6.4.5 Clinical manifestations,.

6.4.6 Differential diagnosis,. 6.4.7 Essential investigations and their interpretation,. 6.4.

8 Management,. 6.5 Black piedra,. 6.5.1 Definition,. 6.5.

2 Geographical distribution,. 6.5.3 The causal organism and its habitat,. 6.5.4 Epidemiology,. 6.

5.5 Clinical manifestations,. 6.5.6 Differential diagnosis,. 6.5.7 Essential investigations and their interpretation,.

6.5.8 Management,. 6.6 Tinea nigra,. 6.6.1 Definition,.

6.6.2 Geographical distribution,. 6.6.3 The causal organism and its habitat,. 6.6.

4 Epidemiology,. 6.6.5 Clinical manifestations,. 6.6.6 Differential diagnosis,. 6.

6.7 Essential investigations and their interpretation,. 6.6.8 Management.